Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TLX vs NAMS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TLX Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

TLX Overall Winner 6-Pillar Tally: TLX 5 – 1 NAMS Matrix Metrics: TLX 8 – 2 NAMS

As of Nov 16, 2026, Telix Pharmaceuticals Limited (TLX) is the stronger overall head-to-head candidate over NewAmsterdam Pharma Company N.V. (NAMS) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TLX carries a Unified Composite Score of 46.4/100 (HOLD) at $8.96 (N/M Forward P/E, 6.2% operating margin), whereas NAMS carries 44.5/100 (HOLD) at $19.74 (108.7x Forward P/E, -900.1% operating margin).

  • Growth vs. Quality Trade-Off: TLX earns the overall head-to-head edge with a stronger Unified Composite Score (46.4/100 HOLD vs. NAMS 44.5/100 HOLD) and 0.84β · 62% Vol risk profile, whereas NAMS leads top-line expansion (+5406.9% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: TLX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.0); meanwhile NAMS is in a Breakdown options structure phase (RSI 45.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TLX vs NAMS
TLX NASDAQ Head-to-Head Winner
Telix Pharmaceuticals Limited American Depositary Shares
Pharmaceutical Preparations
$8.96
-2.98% 1D
Market Cap $3.2B
TTM Revenue $891M
Forward P/E N/M
Beta / 30D Vol 0.84β · 62% Vol
Unified Composite Score
46.4 / 100 HOLD
Tech 64.0 Fund 62.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.7%), weak momentum, RSI 39
RSI-14: 39.0 · SMA20: $9.46 · SMA50: $10.61
NAMS NASDAQ
NewAmsterdam Pharma Company N.V. Ordinary Shares
Pharmaceutical Preparations
$19.74
-1.99% 1D
Market Cap $2.4B
TTM Revenue $26M
Forward P/E 108.7x
Beta / 30D Vol 1.57β · 68% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 51.0 Fund 61.0 Flow 63.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 45.2 · SMA20: $20.16 · SMA50: $21.41

6-Pillar Scorecard Institutional Category Breakdown (TLX 5 – 1 NAMS)

Columns: Metric · TLX · NAMS
1. Valuation Multiples TLX
Forward P/E N/M 108.7x
Trailing P/E 93.6x 108.7x
PEG Ratio N/M N/M
EV / Revenue 3.6x 76.0x
2. Growth & Scale TLX
Revenue Growth (YoY) +22.3% +5406.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $891M $26M
Market Cap $3.2B $2.4B
3. Profitability & Quality TLX
Gross Margin 47.6% 100.0%
Operating Margin 6.2% -900.1%
Net Profit Margin 3.8% 0.0%
Return on Equity (ROE) 7.4% -30.2%
4. Balance Sheet & Cash Flow TLX
Cash Generation (TTM) $70M EBITDA -$151M
Cash Flow Margin 7.8% EBITDA Mgn N/A
Net Cash / Leverage $1.44 Book/Sh · 7.4% ROE $423M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning NAMS
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 202.2% (54th %ile)
Put/Call OI Skew Thin ADR Chain 5.06x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat TLX
OpEx & R&D Intensity 41.4% of Rev ($369M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TLX (8) vs NAMS (2)
Institutional Metric TLX NAMS Criterion Row Edge
Market Capitalization
Scale
$3.2B $2.4B Larger Scale TLX
Trailing P/E Ratio
Valuation
93.6x 108.7x Lower Multiple TLX
Forward P/E Ratio
Valuation
N/M 108.7x Lower Multiple NAMS
Revenue Growth (YoY)
Growth
+22.3% +5406.9% Higher Growth NAMS
Operating Margin (TTM)
Profitability
6.2% -900.1% Higher Margin TLX
Net Profit Margin
Profitability
3.8% 0.0% Higher Margin TLX
Return on Equity (ROE)
Capital Efficiency
7.4% -30.2% Higher ROE TLX
52-Week Range Position
Momentum
39% ($6–$13) 8% ($18–$42) Stronger Trend TLX
Beta / 30D Volatility
Risk Regime
0.84β · 62% Vol 1.57β · 68% Vol Lower Realized Risk TLX
Unified Institutional Score
Composite Signal
46.4 / 100 (HOLD) 44.5 / 100 (HOLD) Higher Composite TLX
Trailing 12M Revenue (USD)
Operating Scale
$891M $26M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
47.6% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.6x EV/Rev N/M PEG · 76.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$70M EBITDA ($1.44 Book/Sh · 7.4% ROE) -$151M ($423M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NAMS +15.78 pp
TLX: -16.23% · NAMS: -0.45%
3M Horizon TLX +2.94 pp
TLX: -24.62% · NAMS: -27.56%
6M Horizon TLX +29.29 pp
TLX: -12.89% · NAMS: -42.18%
1Y Horizon TLX +39.96 pp
TLX: -5.84% · NAMS: -45.8%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TLX vs NAMS. Trailing 12-month operating profitability (TLX 6.2% vs NAMS -900.1%) and valuation multiples (TLX N/M vs NAMS 108.7x Forward P/E) are benchmarked directly in Pillar 4 below.

TLX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$891M
Gross Margin47.6%
Op. Margin6.2%
ROE / Fwd P/E7.4% · N/M
NAMS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$26M
Gross Margin100.0%
Op. Margin-900.1%
ROE / Fwd P/E-30.2% · 108.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TLX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TLX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NAMS BREAKDOWN
131d in phase · OBV ACCUMULATION
Current IV 202.2%
IV Percentile 54th %ile
Put/Call OI Skew 5.06x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact NAMS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TLX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.2B market capitalization and 6.2% operating margin.
OpEx & R&D Reinvestment 41.4% of Rev ($369M)
90D Engineering Disclosures 0 Published
NAMS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.4B market capitalization and -900.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ TLX vs NAMS Key Questions & Quantitative Answers

As of Nov 16, 2026, Telix Pharmaceuticals Limited (TLX) is the stronger overall head-to-head candidate over NewAmsterdam Pharma Company N.V. (NAMS) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TLX carries a Unified Composite Score of 46.4/100 (HOLD) at $8.96 (N/M Forward P/E, 6.2% operating margin), whereas NAMS carries 44.5/100 (HOLD) at $19.74 (108.7x Forward P/E, -900.1% operating margin). Growth vs. Quality Trade-Off: TLX earns the overall head-to-head edge with a stronger Unified Composite Score (46.4/100 HOLD vs. NAMS 44.5/100 HOLD) and 0.84β · 62% Vol risk profile, whereas NAMS leads top-line expansion (+5406.9% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: TLX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.0); meanwhile NAMS is in a Breakdown options structure phase (RSI 45.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TLX leads the Growth & Scale pillar: TLX posts +22.3% YoY revenue growth and +0.0% YoY earnings growth on $891M TTM revenue (47.6% gross margin, 6.2% operating margin), compared with NAMS at +5406.9% YoY revenue growth and +0.0% YoY earnings growth on $26M TTM revenue (100.0% gross margin, -900.1% operating margin). On trailing 12-month operating scale, TLX generates $891M in USD-normalized revenue versus $26M for NAMS. In operating R&D and SG&A reinvestment, TLX deploys 41.4% of Rev ($369M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NAMS.

TLX screens cheaper on headline valuation multiples. TLX trades at N/M Forward P/E, 93.6x Trailing P/E, N/M PEG, and 3.6x EV/Revenue (7.8% EBITDA margin), whereas NAMS trades at 108.7x Forward P/E, 108.7x Trailing P/E, N/M PEG, and 76.0x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TLX (7.4% ROE) versus NAMS (-30.2% ROE) capital efficiency.

In options market volatility and institutional positioning, TLX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.84β · 62% Vol realized risk). By comparison, NAMS carries 202.2% implied volatility (54th %ile, Balanced (25th–60th %ile)), a 5.06x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.57β · 68% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Telix Pharmaceuticals Limited American Depositary Shares (TLX) Research Suite

NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.